Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market
Market Competitors Include Pfizer And Merck & Co
Executive Summary
A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.